Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Telix | History Defined

Aussie imaging agent to help brain cancer patients

The United States Food and Drug Administration has approved Telix Pharmaceutical's Pixclara, an imaging agent to aid in the diagnosis of brain cancer.

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these. David N. Cade, MD, Telix Group Chief Medical Officer...

CSL, Mayne Pharma expect to dodge new US pharma tariffs

CSL, Mayne Pharma expect to dodge new US pharma tariffs

Both CSL and Adelaide-based woman's health company Mayne Pharma say they won't be impacted by Donald Trump's new pharmaceutical tariffs.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance

Telix Pharmaceuticals (NASDAQ:TLX) updated on Tuesday its commercial and operational performance for the third quarter of fiscal 2025.

Telix Gets Second FDA Rejection For Kidney Cancer Drug

On Thursday, Telix Pharmaceuticals Limited (NASDAQ:TLX) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix, 89Zr-DFO girentuximab), an investigational PET2 agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC).

Telix Pharmaceuticals Trial Enter Critical Stage, Analyst Predicts Big Gains

Telix Pharmaceuticals Ltd (NASDAQ:TLX) is the world's most "diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company," according to HC Wainwright.

Aussie shares dip slightly, ending 10-day win streak

The ASX200 has finished three points lower, just enough to snap its longest winning streak since early-2015.

inkl

Read news from The Economist, FT, and more,
with one subscription

Telix posts first profit as sales triple to $502m

Telix posts first profit as sales triple to $502m

Melbourne-based radiation oncology business Telix Pharmaceuticals has made its first-ever profit after strong sales for its prostate cancer imaging agent.

Aussie biomedical innovations will revolutionise the lives of quadriplegics and cancer patients

Aussie biomedical innovations will revolutionise the lives of quadriplegics and cancer patients

Australian companies have made significant progress in biomedical technologies to bring new remedies to people who need them most.

Australian biotech developments can give independence to quadriplegics

Australian biotech developments can give independence to quadriplegics

Australian companies are making significant strides in biomedical technologies that deliver remedies in new ways

1

People

212,180 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Securities and Exchange Commission

the Australian Securities Exchange

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Prostate Cancer

Places

416,087 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play